Kynam Capital Management, LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001907884

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q2 2026 · 32 positions · Total reported value $1.81B · Top-10 concentration 72.7% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 48.8% · 4 new · 7 cut · 9 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +14.0% · vs SPY -0.8% · Prev Value $1.55B — last quarter positions weighted by this quarter price moves · ranking

In its Q2 2026 13F filing, Kynam Capital Management, LP disclosed 32 equity positions with a combined reported value of $1.81B. The filing implies a focused portfolio: its ten largest positions account for 72.7% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were CLDX ($198.07M), SNDX ($175.99M), PCVX ($169.88M). By sector, the heaviest allocations are Health Care 100.0%. Versus the prior quarter, allocation shifted toward Health Care (+5.7pp) and away from Other (-5.7pp).

Versus the prior quarter, Kynam Capital Management, LP opened 4 new positions, trimmed 7 and fully exited 9, a turnover rate of 48.8% of positions. The portfolio's overlap with the prior quarter was 68% of names.

The largest new positions opened in Q2 2026 were SMMT ($17.48M), INSM ($10.66M), PBLS ($6.84M).

Of the 9 positions fully exited versus the prior quarter, the largest were KALV ($36.66M), APLS ($33.19M), RVMD ($20.18M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • SMMT SUMMIT THERAPEUTICS INC · $17.48M
  • INSM INSMED INC · $10.66M
  • PBLS PARABILIS MEDICINES INC · $6.84M
  • TRAW Traws Pharma Inc · $71.17K

Fully Exited (vs previous quarter)

  • KALV KALVISTA PHARMACEUTICALS INC · prev qtr: $36.66M
  • APLS APELLIS PHARMACEUTICALS INC · prev qtr: $33.19M
  • RVMD REVOLUTION MEDICINES INC COM · prev qtr: $20.18M
  • SLNO SOLENO THERAPEUTICS INC · prev qtr: $18.75M
  • EVMN EVOMMUNE INC · prev qtr: $14.38M
  • DSGN DESIGN THERAPEUTICS INC · prev qtr: $8.35M
  • WVE WAVE LIFE SCIENCES INC · prev qtr: $7.00M
  • CLYM CLIMB BIO INC · prev qtr: $6.87M

Insider Transactions (Form 4)

Latest Kynam Capital Management, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Kynam Capital Management, LP files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 32 positions worth $1.81B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • SEC registration: 801-126187 (status: Approved), registered 2022-07-22
  • Regulatory AUM (Form ADV): $2.41B as of 2026-04-10
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 1 private funds, of which 1 hedge funds

Portfolio Structure

  • 32 positions · $1.81B reported value (Q2 2026)
  • Top 10 holdings = 72.7% of reported value
  • Largest position: CLDX (CELLDEX THERAPEUTICS INC NEW) at 10.9%
  • Average position size: $56.54M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 4 new, 12 added, 7 reduced, 9 exited
  • 9 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: Kynam Capital Management's Q2 2026 rebalancing indicates a conservative approach with a preference for holding or reducing positions in health care sector stocks. This suggests a cautious market view, possibly due to uncertainties or a belief in the stability of the health care sector. 2. Key Moves: - Added Positions: VRDN (Viridian Therapeutics) and TVTX (Traverse Therapeutics) were added significantly, indicating a strategic shift towards biotechnology within the health care sector. - Reduced Positions: The fund reduced holdings in CLDX (CellDex Therapeutics), COGT (Cogent Biosciences), VERA (Vera Therapeutics), and BEAM (Beam Therapeutics), which could reflect a reevaluation of these companies' prospects or market sentiment. - Hold Positions: Most other holdings were held steady, including SNDX (Syndax Pharmaceuticals) and PCVX (Vaxcyte Inc), showing a level of confidence in these companies. 3. Portfolio Structure: - Passive/Active: The rebalancing appears more active, as the fund is making significant changes to holdings rather than maintaining a passive, index-tracking approach. - Sector Bias: The health care sector is a clear bias, with a significant portion of the portfolio allocated to it. - Risk Appetite: The risk appetite seems moderate, with a focus on holding or reducing positions rather than aggressive additions. 4. Per-Holding One-Liner: - CLDX: CellDex Therapeutics Inc., a clinical-stage biopharmaceutical company developing therapies for blood cancers and solid tumors. - SNDX: Syndax Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing treatments for cancer. - PCVX: Vaxcyte Inc., a biotechnology company focused on the development of live attenuated bacterial vaccines. - COGT: Cogent Biosciences Inc., a clinical-stage biotechnology company focused on the development of novel treatments for autoimmune diseases. - VERA: Vera Therapeutics Inc., a biopharmaceutical company developing therapies for rare genetic diseases. - VRDN: Viridian Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing therapies for rare and orphan diseases. - TVTX: Traverse Therapeutics Inc., a biotechnology company focused on developing therapies for central nervous system disorders. - BEAM: Beam Therapeutics Inc., a biotechnology company focused on developing CRISPR-based therapies for genetic diseases. - URGN: UroGen Pharma Ltd., a biopharmaceutical company focused on the development and commercialization of innovative therapies for urological conditions. - LEGN: Legend Biotech Corp Sponsored, a clinical-stage biotechnology company developing novel cancer immunotherapies. 5. One-Sentence Style Summary: Kynam Capital Management's Q2 2026 rebalancing reflects a cautious yet selectively aggressive approach, focusing on health care sector opportunities with a preference for biotechnology stocks and strategic reductions in other holdings.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 100.0%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 5.32M $198.07M 10.95%
10.95%
Reduce
2 8.05M $175.99M 9.73%
9.73%
Hold
3 2.92M $169.88M 9.39%
9.39%
Hold
4 3.67M $141.92M 7.84%
7.84%
Reduce
5 2.89M $124.01M 6.85%
6.85%
Reduce
6 6.45M $118.56M 6.55%
6.55%
Add
7 2.00M $113.62M 6.28%
6.28%
Add
8 2.84M $97.50M 5.39%
5.39%
Reduce
9 2.43M $89.58M 4.95%
4.95%
Add
10 3.00M $86.67M 4.79%
4.79%
Add
11 21.70M $81.39M 4.50%
4.50%
Add
12 3.30M $61.74M 3.41%
3.41%
Add
13 3.11M $56.71M 3.13%
3.13%
Hold
14 934.80K $51.60M 2.85%
2.85%
Hold
15 1.38M $43.66M 2.41%
2.41%
Add
16 1.19M $28.98M 1.60%
1.60%
Hold
17 872.56K $28.97M 1.60%
1.60%
Hold
18 2.52M $25.23M 1.39%
1.39%
Reduce
19 661.79K $22.88M 1.26%
1.26%
Add
20 1.20M $17.48M 0.97%
0.97%
New
21 2.42M $12.87M 0.71%
0.71%
Add
22 100.00K $10.66M 0.59%
0.59%
New
23 1.24M $10.52M 0.58%
0.58%
Add
24 6.84M $8.75M 0.48%
0.48%
Hold
25 532.98K $8.50M 0.47%
0.47%
Add
26 3.81M $7.66M 0.42%
0.42%
Add
27 250.00K $6.84M 0.38%
0.38%
New
28 2.50M $4.41M 0.24%
0.24%
Hold
29 1.57M $2.91M 0.16%
0.16%
Hold
30 96.74K $996.43K 0.06%
0.06%
Reduce
31 457.86K $792.09K 0.04%
0.04%
Reduce
32 84.40K $71.17K 0.00%
0.00%
New

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q3) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q2)

P 70% R 70% F1 70% (modelled on 2026-Q1; 7/10 hit)

Historical Backtest (10 quarters)

Avg precision 81% · recall 81% · F1 81% · avg rank error 2.0 · Top-10 turnover 20%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 70% 70% 70% NTRA · SNDX · CLDX · PCVX · VERA · PTGX · IMGN · MOR · COGT · LQDA NTRA · SNDX · CLDX · VERA · COGT · DVAX · PCVX · VRTX · LQDA · BCRX
2024-Q2 80% 80% 80% NTRA · SNDX · CLDX · COGT · VERA · DVAX · PCVX · VRTX · BCRX · LQDA NTRA · VRTX · CLDX · SNDX · SPY · DVAX · COGT · INSM · PCVX · VERA
2024-Q3 70% 70% 70% NTRA · VRTX · CLDX · SNDX · SPY · DVAX · COGT · INSM · BCRX · PCVX NTRA · PCVX · CLDX · SNDX · COGT · DVAX · VERA · BCRX · CGON · VRDN
2024-Q4 90% 90% 90% NTRA · PCVX · CLDX · SNDX · DVAX · COGT · CGON · BCRX · VERA · VRDN NTRA · PCVX · SPY · CLDX · SNDX · DVAX · CGON · COGT · BCRX · VRDN
2025-Q1 80% 80% 80% NTRA · PCVX · SPY · CLDX · SNDX · DVAX · CGON · COGT · VRDN · BCRX NTRA · PCVX · CLDX · SNDX · BCRX · CGON · VRDN · VERA · COGT · IMCR
2025-Q2 90% 90% 90% NTRA · PCVX · CLDX · SNDX · VRDN · CGON · BCRX · VERA · IMCR · COGT CLDX · PCVX · VERA · SNDX · BCRX · CGON · VRDN · COGT · BEAM · IMCR
2025-Q3 100% 100% 100% CLDX · PCVX · VERA · SNDX · BCRX · VRDN · CGON · COGT · BEAM · IMCR CLDX · SNDX · VERA · COGT · PCVX · VRDN · CGON · BCRX · BEAM · IMCR
2025-Q4 80% 80% 80% CLDX · SNDX · VERA · COGT · PCVX · VRDN · CGON · BCRX · BEAM · IMCR COGT · VERA · SNDX · CLDX · PCVX · BCRX · VRDN · TYRA · CGON · CTMX
2026-Q1 80% 80% 80% COGT · VERA · SNDX · CLDX · PCVX · BCRX · CTMX · VRDN · NRIX · TYRA SNDX · CLDX · PCVX · COGT · VERA · BEAM · CTMX · BCRX · VRDN · CGEM
2026-Q2 ★ 70% 70% 70% SNDX · CLDX · PCVX · COGT · VERA · BEAM · CTMX · BCRX · CGEM · URGN CLDX · SNDX · PCVX · COGT · VERA · VRDN · TVTX · BEAM · URGN · LEGN

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

FAQ

What did Kynam Capital Management, LP buy in 2026-Q2?

In its 2026-Q2 13F filing, Kynam Capital Management, LP reported 32 equity positions worth $1.81B in aggregate; its largest disclosed positions were CLDX ($198.07M), SNDX ($175.99M), PCVX ($169.88M).

How large is Kynam Capital Management, LP's portfolio?

Kynam Capital Management, LP reported $1.81B of long equity holdings across 32 positions as of 2026-Q2. Top-10 holdings account for 72.7% of reported value.

What is Kynam Capital Management, LP's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/kynam-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →